An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

Siplizumab

40 mg doses

Trial Locations (1)

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors

collaborator

ITB-Med LLC

INDUSTRY

lead

University of Alabama at Birmingham

OTHER